Image 1_Predicting ventilator-associated lower respiratory tract infection outcomes using sequencing-based early microbiological response: a proof-of-concept prospective study.tif by Ji Zhou (481629)

“…The RQR was calculated as the quantification of A. baumannii determined by QtNGS after treatment to pretreatment. RQR significantly increased on day 4 in the non-survival group (median 5.285), and decreased in the survival group (median 0.1864). …”

The expression of PAX7 and MYOD1 correlate with differential expression of diverse chemokines in HuMuSC. by Katharine Striedinger (15503387)

“…Using linear regression PAX7 slope varies significantly p = 0.0001 and MYOD1 slope also varies significantly p = 0.05 n = 3 <b>(b)</b> Heat map displaying the expression levels of all cytokine protein detected in HuMuSC from collection as they activate progressively at day 0, day 3 and day 6 <i>in vitro</i>, using the high throughput proteomic Multiplex assay. …”

Supplementary Material for: Long-Term Effects of Cognitive Behavioral Therapy on Sickness Absence and Cognitive Functioning in Patients with Stress-Related Disorders: Secondary Res... by figshare admin karger (2628495)

“…Results CBT and GHP had comparable effects on SA and cognitive functioning with no significant between-group effects (all p > .05). Analyzing effects across the entire sample, the number of SA days among those with any SA did not significantly change (p = .946) but the likelihood of having any SA decreased significantly by the 1YFU (OR = .92, 95% CI [.87, .96], p < .001). …”

Table 3_Predicting ventilator-associated lower respiratory tract infection outcomes using sequencing-based early microbiological response: a proof-of-concept prospective study.docx by Ji Zhou (481629)

“…The RQR was calculated as the quantification of A. baumannii determined by QtNGS after treatment to pretreatment. RQR significantly increased on day 4 in the non-survival group (median 5.285), and decreased in the survival group (median 0.1864). …”

Table 1_Predicting ventilator-associated lower respiratory tract infection outcomes using sequencing-based early microbiological response: a proof-of-concept prospective study.doc by Ji Zhou (481629)

“…The RQR was calculated as the quantification of A. baumannii determined by QtNGS after treatment to pretreatment. RQR significantly increased on day 4 in the non-survival group (median 5.285), and decreased in the survival group (median 0.1864). …”

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Short-Term Effects of Dark Chocolate on Choroidal Parameters in Myopic Patients During Near Work by Meng Lin (591782)

“…Both experiments found that the choroidal blood flow decreased significantly after near work, but the ChT decreased significantly only after consumption of dark chocolate. …”

Image 4_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

“…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”

Image 2_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

“…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”

Image 1_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

“…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”

Image 5_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

“…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”

Table 1_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.docx by Xiao Li (107004)

“…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”

Image 3_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

“…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”

Data Sheet 1_Dynamic electrophysiological changes in abnormal brain cavities post-ischemic stroke.docx by Ugur Kilic (9927866)

“…We observed significant decreases in power across different conditions (p < 0.0001), and this decrease varied in different locations. …”

5OMV Inhibits HMGB1-Induced Microvascular Branch Formation in Rat Abdominal Aortic Rings. by Wenyue Hou (10203722)

“…Mean values showing significant differences between the control group and the HMGB1-treated group are indicated by *(<i>P</i> < 0.05) or ** (<i>P</i> < 0.01). …”

Image 1_The advanced lung cancer inflammation index as a predictor of kidney stone risk in men: a cross-sectional analysis.tif by Yan Zhou (6523)

“…For every one-unit increase in ALI score, the risk of having kidney stones decreased by 22.7% (odds ratio = 0.773, 95% CI: 0.675–0.885, P < 0.001). …”